Alacrita Life Science Consulting Alacrita Life Science Consulting
  • Our Services
    • Product Development
      • Research & IP Evaluation
      • Preclinical Strategy & Execution
      • Clinical Development
      • Regulatory Affairs
      • CMC Consulting
      • Interim Chief Medical Officer
    • Strategy & Commercialization
      • Opportunity Mapping
      • Business Plans & Fundraising Support
      • New Product Planning
      • Launch Planning
    • Business Development
      • Due Diligence
      • Valuations
      • In-Licensing & Asset Scouting
      • Out-Licensing, Partnering & Deal-making
    • Expert Witness Services
    • By Client Type
      • Biotech
      • Virtual & Semi-Virtual Biotechs
      • Pharmaceutical Companies
      • Investors
      • Tech Transfer Offices
      • Animal Health Companies
    • By Product Modality
      • Antibodies, ADCs
      • Cell Therapies
      • Drug Discovery Platforms
      • Gene Therapies
      • Microbiome Drugs
      • Peptides & Proteins
      • Radiopharmaceuticls
      • Small Molecules
      • Other Product Modalities
    • By Disease Area
      • CNS
      • Digestive & GI
      • Endocrine & Metabolic
      • Fibrosis
      • Hematology
      • Immunology
      • Oncology
      • Respiratory
      • Other Disease Areas
  • Core Team
    • Alastair Southwell
    • Anthony Walker
    • Saadia Anastasiou
    • Michael Lombardo
    • Lucas Rodriguez
    • Mark Philip
    • Nigel Burns
    • Gary Mansfield
    • Christine McCarthy
    • Stuart Hendry
    • Simon Turner
    • Pierre Dodion
  • Consulting Network
  • Resources
    • Case Studies
    • Blog
    • News
    • Whitepapers
  • Careers
  • Contact

Blog

  • news and resources
  • Blog
  • All
  • Product Development
  • Clinical Development
  • Business Development
  • Strategy & Commercialization
  • Valuations
  • Regulatory Affairs
  • Opportunity Mapping
  • Research & IP evaluation
  • Technology Transfer
  • Business Strategy
  • Cell Therapy
  • Clinical Development Strategy
  • Due Diligence
  • Fibrosis
  • Interim Chief Medical Officer
  • Microbiome
  • New Product Planning
  • Oncology
  • Partnering
  • Partnering & deal-making
  • Pharma Licensing
  • Preclinical Development

Kerry Noonan

Recent Posts

What’s the difference between biotech and pharma? 

What’s the difference between biotech and pharma? How are biotechnology drugs different from traditional pharmaceuticals, and how are biotech companies different to pharma companies?
Learn More

Colin Miller, medical imaging consultant, presents poster at OARSI meeting

Medical imaging expert and Alacrita Partner, Colin G Miller PhD, presented his poster titled "Standardization of imaging reads for eligibility assessment of patients — Component of a risk mitigation...
Learn More

Post EMA approval: how soon can products be sold?

Question: After EMA approval, are sales of a pharmaceutical allowed in EU5, before pricing is approved? What is the soonest a company can sell a pharmaceutical agent in Europe after approval?
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

  • Strategy and Commercialization Learn more
  • Product Development Learn more
  • Business Development Learn more

© 2009-25 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

  • Privacy Notice

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.

Alacrita Life Science Consulting Alacrita Life Science Consulting